Dr. Ignacio Duran titled his discussion of abstracts 2595MO, 2600MO, 2610MO: Bringing any clarity into the non-clear or ...

HER-2 targeted antibody-drug conjugate monotherapy has demonstrated efficacy in the post-chemotherapy setting for ...

In the phase 1 portion of the trial, two doses of gedatolisib were administered IV on an intermittent schedule (Days 1, 8, 15 ...

Dr. Laurence Albiges presented the poster Characteristics and real-world adherence to ESMO guidelines of patients with advanced Renal Cell Carcinoma (aRCC) in the era of immuno-oncology-based (IO) ...

Of testicular cancer survivors aged <30 years at diagnosis, 60% fathered a post-index child, compared to 73% of the controls (p<0.001). Testicular cancer survivors aged ≥30 years had considerably ...

(UroToday.com) The 2025 European Society of Medical Oncology (ESMO) Annual Congress held in Berlin, Germany, was host to the session Mini Oral session 2: GU tumours, renal & urothelial Dr. Tian Zhang ...

Progression-free survival on first subsequent therapy (i.e., PFS2) was significantly prolonged with both enzalutamide ...

The 2025 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Alicia K. Morgans discussing ...

In the exploratory subgroup analysis of chRCC by PD-L1 CPS status, there was a trend favoring nivolumab plus ipilimumab for ...

Dr. Ma emphasized that intratumor mycobiome dysbiosis is correlated with Clear Cell Renal Cell Carcinoma (ccRCC). He presented findings from an analysis of fungal communities in ccRCC, using ...

Dr. Simsek began by emphasizing that their group had previously shown that CD8+ T cells expressing PD-1 but lacking TIM-3 or LAG-3 are associated with improved clinical outcomes to anti–PD-1 ...

At the ESMO 2025 annual meeting, Dr. Hansen and colleagues presented the first-in-human data of 212 Pb-ADVC001 in patients ...